Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease
Alzheimer’s disease, a devastating neurodegenerative disorder, is characterized by progressive cognitive decline, primarily due to amyloid-beta protein deposition and tau protein phosphorylation. Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the p...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2026-02-01
|
| Series: | Neural Regeneration Research |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/NRR.NRR-D-24-00846 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850236151356456960 |
|---|---|
| author | Sha Sha Lina Ren Xiaona Xing Wanshu Guo Yan Wang Ying Li Yunpeng Cao Le Qu |
| author_facet | Sha Sha Lina Ren Xiaona Xing Wanshu Guo Yan Wang Ying Li Yunpeng Cao Le Qu |
| author_sort | Sha Sha |
| collection | DOAJ |
| description | Alzheimer’s disease, a devastating neurodegenerative disorder, is characterized by progressive cognitive decline, primarily due to amyloid-beta protein deposition and tau protein phosphorylation. Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the progression of Alzheimer’s disease. Conventional drugs, such as donepezil, can only alleviate symptoms and are not able to prevent the underlying pathological processes or cognitive decline. Currently, active and passive immunotherapies targeting amyloid-beta and tau have shown some efficacy in mice with asymptomatic Alzheimer’s disease and other transgenic animal models, attracting considerable attention. However, the clinical application of these immunotherapies demonstrated only limited efficacy before the discovery of lecanemab and donanemab. This review first discusses the advancements in the pathogenesis of Alzheimer’s disease and active and passive immunotherapies targeting amyloid-beta and tau proteins. Furthermore, it reviews the advantages and disadvantages of various immunotherapies and considers their future prospects. Although some antibodies have shown promise in patients with mild Alzheimer’s disease, substantial clinical data are still lacking to validate their effectiveness in individuals with moderate Alzheimer’s disease. |
| format | Article |
| id | doaj-art-4b09f30db8f042eb905bea3e6f04d904 |
| institution | OA Journals |
| issn | 1673-5374 1876-7958 |
| language | English |
| publishDate | 2026-02-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Neural Regeneration Research |
| spelling | doaj-art-4b09f30db8f042eb905bea3e6f04d9042025-08-20T02:02:01ZengWolters Kluwer Medknow PublicationsNeural Regeneration Research1673-53741876-79582026-02-0121257758710.4103/NRR.NRR-D-24-00846Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s diseaseSha ShaLina RenXiaona XingWanshu GuoYan WangYing LiYunpeng CaoLe QuAlzheimer’s disease, a devastating neurodegenerative disorder, is characterized by progressive cognitive decline, primarily due to amyloid-beta protein deposition and tau protein phosphorylation. Effectively reducing the cytotoxicity of amyloid-beta42 aggregates and tau oligomers may help slow the progression of Alzheimer’s disease. Conventional drugs, such as donepezil, can only alleviate symptoms and are not able to prevent the underlying pathological processes or cognitive decline. Currently, active and passive immunotherapies targeting amyloid-beta and tau have shown some efficacy in mice with asymptomatic Alzheimer’s disease and other transgenic animal models, attracting considerable attention. However, the clinical application of these immunotherapies demonstrated only limited efficacy before the discovery of lecanemab and donanemab. This review first discusses the advancements in the pathogenesis of Alzheimer’s disease and active and passive immunotherapies targeting amyloid-beta and tau proteins. Furthermore, it reviews the advantages and disadvantages of various immunotherapies and considers their future prospects. Although some antibodies have shown promise in patients with mild Alzheimer’s disease, substantial clinical data are still lacking to validate their effectiveness in individuals with moderate Alzheimer’s disease.https://journals.lww.com/10.4103/NRR.NRR-D-24-00846alzheimer’s diseaseamyloid depositsamyloid-betaantibodycognitive dysfunctiondementiaimmunotherapyoligomerpreventive immunizationtau hyperphosphorylation |
| spellingShingle | Sha Sha Lina Ren Xiaona Xing Wanshu Guo Yan Wang Ying Li Yunpeng Cao Le Qu Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease Neural Regeneration Research alzheimer’s disease amyloid deposits amyloid-beta antibody cognitive dysfunction dementia immunotherapy oligomer preventive immunization tau hyperphosphorylation |
| title | Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease |
| title_full | Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease |
| title_fullStr | Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease |
| title_full_unstemmed | Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease |
| title_short | Recent advances in immunotherapy targeting amyloid-beta and tauopathies in Alzheimer’s disease |
| title_sort | recent advances in immunotherapy targeting amyloid beta and tauopathies in alzheimer s disease |
| topic | alzheimer’s disease amyloid deposits amyloid-beta antibody cognitive dysfunction dementia immunotherapy oligomer preventive immunization tau hyperphosphorylation |
| url | https://journals.lww.com/10.4103/NRR.NRR-D-24-00846 |
| work_keys_str_mv | AT shasha recentadvancesinimmunotherapytargetingamyloidbetaandtauopathiesinalzheimersdisease AT linaren recentadvancesinimmunotherapytargetingamyloidbetaandtauopathiesinalzheimersdisease AT xiaonaxing recentadvancesinimmunotherapytargetingamyloidbetaandtauopathiesinalzheimersdisease AT wanshuguo recentadvancesinimmunotherapytargetingamyloidbetaandtauopathiesinalzheimersdisease AT yanwang recentadvancesinimmunotherapytargetingamyloidbetaandtauopathiesinalzheimersdisease AT yingli recentadvancesinimmunotherapytargetingamyloidbetaandtauopathiesinalzheimersdisease AT yunpengcao recentadvancesinimmunotherapytargetingamyloidbetaandtauopathiesinalzheimersdisease AT lequ recentadvancesinimmunotherapytargetingamyloidbetaandtauopathiesinalzheimersdisease |